KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) FCF Margin (2018 - 2025)

Vir Biotechnology's FCF Margin history spans 8 years, with the latest figure at 40.93% for Q4 2025.

  • On a quarterly basis, FCF Margin rose 68341.0% to 40.93% in Q4 2025 year-over-year; TTM through Dec 2025 was 578.52%, a 7394.0% increase, with the full-year FY2025 number at 578.52%, up 3283.0% from a year prior.
  • FCF Margin hit 40.93% in Q4 2025 for Vir Biotechnology, up from 69952.92% in the prior quarter.
  • Over the last five years, FCF Margin for VIR hit a ceiling of 2312.48% in Q2 2022 and a floor of 69952.92% in Q3 2025.
  • Historically, FCF Margin has averaged 5655.19% across 5 years, with a median of 433.64% in 2023.
  • Biggest five-year swings in FCF Margin: soared 794723bps in 2024 and later crashed -6263157bps in 2025.
  • Tracing VIR's FCF Margin over 5 years: stood at 1.22% in 2021, then surged by 3835bps to 45.64% in 2022, then crashed by -1529bps to 652.06% in 2023, then fell by -11bps to 724.34% in 2024, then surged by 94bps to 40.93% in 2025.
  • Business Quant data shows FCF Margin for VIR at 40.93% in Q4 2025, 69952.92% in Q3 2025, and 10111.78% in Q2 2025.